Unlike AML with mutated TP53, which is a novel subtype with a homogeneously dismal prognosis, AML patients with RUNX1mut seemed to have a heterogeneous prognosis, depending on the host and disease factors [50,51,52,53,54,55]. This evidence concerns the gene TP53 and acute myeloid leukemia.